Alnylam Pharmaceuticals, Inc. (ALNY) Stock Grade

About Alnylam Pharmaceuticals, Inc.'s fundamentals

Alnylam Pharmaceuticals is a large-cap biotechnology company with a market capitalization of $52.1 billion that is experiencing strong revenue growth of 65.2% year-over-year, though it carries a notably elevated P/E ratio of 166.0 relative to its current earnings. The company maintains an 8.5% net profit margin and generates a robust 39.8% return on equity, indicating efficient capital deployment despite its high valuation multiple. As a growth-stage biotech firm, Alnylam does not currently pay a dividend, with shareholders relying on potential capital appreciation rather than income generation.